Dr. Seth D. Cohen, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 966
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA06969100 -
Hematology & Oncology Physician
NJ license MA06969100
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Robert Wood Johnson University Hospital New Brunswick, NJ
- Ocean Medical Center Brick, NJ
- Community Medical Center Toms River, NJ
- Monmouth Medical Center Long Branch, NJ
- Monmouth Medical Center-Southern Campus Lakewood, NJ
Medical groups
- Barnabas Health Medical Group, PC (262 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 966
- Services billed
- 6,288
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 2,780 | 720 |
| Insertion of needle into vein for collection of blood sample | 1,230 | 474 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 305 | 154 |
| Established patient office or other outpatient visit, 20-29 minutes | 160 | 81 |
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 68 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 23 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in West Long Branch, NJ | 251 |
| Ondansetron Hcl Other prescribers in West Long Branch, NJ | 177 |
| Verzenio (abemaciclib) | 133 |
| Levothyroxine Sodium Other prescribers in West Long Branch, NJ | 121 |
| Oxycodone Hcl Other prescribers in West Long Branch, NJ | 99 |
| Acyclovir Other prescribers in West Long Branch, NJ | 92 |
| Prednisone Other prescribers in West Long Branch, NJ | 86 |
| Dexamethasone Other prescribers in West Long Branch, NJ | 74 |
| Alprazolam Other prescribers in West Long Branch, NJ | 71 |
| Orgovyx (relugolix) | 65 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 64 payments worth $873 in total to this clinician.
| Pfizer Inc. | $216 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $199 |
| Daiichi Sankyo Inc. | $137 |
| Novartis Pharmaceuticals Corporation | $72.85 |
| Array Biopharma Inc | $36.81 |
| Astellas Pharma US Inc | $36.24 |
| Gilead Sciences, Inc. | $35.32 |
| Regeneron Healthcare Solutions, Inc. | $34.89 |
| Food and Beverage | $769 |
|---|---|
| Education | $104 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. May 15, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Daiichi Sankyo Inc. Jun 12, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Daiichi Sankyo Inc. May 8, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Astellas Pharma US Inc May 5, 2025 | Education Vyloy · Oncology · in-kind | $18.12 |
| Astellas Pharma US Inc May 5, 2025 | Education Vyloy · Oncology · in-kind | $18.12 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $20,033 in research payments for these studies, mostly to the institutions running them.
- The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.